The case for a descriptive generic nomenclature: clarification of immunostaining criteria for PCA-1, ANNA-1, and ANNA-2 autoantibodies.
Lennon
V A
VA
D000918:Antibody Specificity; D001323:Autoantibodies / Q000032:analysis / Q000145:classification*; D002531:Cerebellum / Q000166:cytology / Q000276:immunology* / Q000473:pathology; D002999:Clone Cells; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis / Q000145:classification*; D007150:Immunohistochemistry; D007413:Intestinal Mucosa / Q000166:cytology / Q000276:immunology; D009130:Muscle, Smooth / Q000166:cytology / Q000276:immunology / Q000294:innervation; D009474:Neurons / Q000166:cytology / Q000276:immunology* / Q000473:pathology; D010257:Paraneoplastic Syndromes / Q000276:immunology / Q000473:pathology; D011689:Purkinje Cells / Q000166:cytology / Q000276:immunology / Q000473:pathology; D011994:Recombinant Proteins / Q000032:analysis; D009626:Terminology as Topic
D001323:Autoantibodies; D007074:Immunoglobulin G; D011994:Recombinant Proteins